Yiling Pharmaceutical issued a notice that it had received a certificate of drug registration granted by the Pharmaceutical and Herbal Medicine Registration and Control Administration of Kuwait that certified its drug - Lianhua Qingwen Capsules - as a herbal medicine to be registered in Kuwait. As the notice indicated, Lianhua Qingwen Capsules was approved to be registered as a drug to "treat symptoms such as fever, cough, debilitation, sore muscles, nasal obstruction, a runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral diseases such as seasonal influenza, influenza, H1N1, SARS, and mild and moderate cases of COVID-19, with the efficacy of lung clearing and detoxication." It's the first time that Lianhua Qingwen has been granted permission in countries other than China to treat symptoms caused by mild and moderate cases of COVID-19. As of now, Lianhua Qingwen has been allowed access to the markets in 15 countries and regions, including Brazil, Romania, Singapore, and the Philippines.